Drugs Medical Pharma

Gilead Sciences to acquire US-based Ouro Medicines for up to $2 billion 

Gilead Sciences, Inc., will acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases, for.

Read More